r Lysophosphatidic acid (LPA) is an itch mediator, but not a pain mediator by a cheek injection model.
Introduction
The sensation of itch, formally called pruritus, is defined as 'an unpleasant cutaneous sensation which provokes a desire to scratch' (Rothman, 1941) . Pruritus is caused by exogenous factors and is also accompanied by diseases such as atopic dermatitis, neurogenic lesions, uremia and cholestasis (Ikoma et al. 2006) . Many itch-inducing substances, called pruritogens, have been shown to activate receptors expressed in primary sensory neurons. These pruritogens are thought to trigger pruritogenic signals that are transmitted to the CNS to evoke an itch sensation (Ikoma et al. 2006; Akiyama & Carstens, 2013; Liu & Ji, 2013; Han & Dong, 2014; Zhang, 2015) . Lysophosphatidic acid (LPA) is known to be a pruritogen, but the mechanism by which it affects primary sensory neurons to elicit itching remains unclear (Liu & Ji 2013; Han & Dong, 2014; Zhang, 2015) .
LPA is a small, ubiquitous phospholipid that plays important roles in cell survival, apoptosis, motility, shape formation, differentiation and other processes (Choi et al. 2010; Tigyi, 2010; Kihara et al. 2014) . LPA was identified as a pruritogen present in the sera of cholestatic patients with pruritus, and the activity of LPA-producing enzymes correlated positively with itch intensity in these patients (Kremer et al. 2010) . In rodent models, LPA is both a pruritogen that induces itch-related behaviours (Hashimoto et al. 2004; Kremer et al. 2010; Alemi et al. 2013) , and an algogen, a pain-inducing molecule that causes acute pain-related behaviours (Nieto-Posadas et al. 2012) . Thus, whether LPA acts as a pruritogen, an algogen or both to affect the peripheral nervous system is unclear.
Transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) are key molecules in itch and pain signalling, and are members of the TRP channel superfamily that in mammals includes 28 members (Wu et al. 2010) . Both TRPA1 and TRPV1 are non-selective Ca 2+ -permeable cation channels that are expressed in neurons of dorsal root ganglion (DRG), trigeminal ganglion (TG) and nodose ganglion (Caterina et al. 2000; Story et al. 2003) and transmit somatosensory signals. TRPA1 has been reported to cause pain (Bautista et al. 2006) as well as itch (Wilson et al. 2011 (Wilson et al. , 2013 Morita et al. 2015) ; similarly, TRPV1 also induces both pain (Caterina et al. 2000) and itch sensations (Shim et al. 2007) . Given that these channels play critically important roles in both pain and itch sensations, we hypothesized that TRPA1 and TRPV1 are involved in the action of LPA. Thus, in this study we aimed to clarify the physiological role of LPA and investigate the detailed mechanistic pathways involved in its action as well as the role of the TRPA1 and TRPV1 channels in this pathway.
Methods

Ethical approval
All procedures involving the care and use of animals were approved by the institutional Animal Care and Use Committee of the National Institute of Natural Sciences (no. 16A074) and carried out in accordance with the National Institutes of Health Guide for the care and use of laboratory animals (NIH publication No. 85-23. Revised, 1985) .
Animals
Male C57BL/6N mice (6-12 weeks old) were housed at one to six animals per cage in a controlled environment (12 h light/dark cycle; 22-25°C; 50-60% humidity) with food and water provided ad libitum. All experiments were performed during the light cycle. TRPA1-knockout (KO) and TRPV1KO mice were kindly provided by Dr David Julius (University of California, San Francisco). TRPA1TRPV1DKO mice were obtained by crossbreeding TRPA1KO and TRPV1KO mice.
Chemicals
LPA (1-oleoyl), dioctanoylglycerol pyrophosphate (DGPP), lysophosphatidylcholine (LPC; 1-oleoyl) and phosphatidic acid (PA; 1,2-dioleoyl) were obtained from Avanti Polar Lipids (Alabaster, AL, USA). Allyl isothiocyanate (AITC) and carvacrol were obtained from Wako Pure Chemical Industries (Osaka, Japan). Capsaicin, ionomycin, capsazepine and lysophosphatidylinositol (LPI; from soybeans) were obtained from Sigma-Aldrich (St Louis, MO, USA). A-967079 was obtained from StressMarq Bioscience (Victoria, BC, Canada). Fura-2-acetoxymethyl ester was obtained from Thermo Fisher Scientific (Waltham, MA, USA). H2L 5765834 and TC LPA5 4 were obtained from Tocris Bioscience (Ellisville, MO, USA). AM095 was obtained from Amira Pharmaceuticals (New York, NY, USA).
Edelfosine, bromoenol lactone (BEL), 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) and U-73122 were obtained from Cayman Chemical (Ann Arbor, MI, USA). D609 was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Stock solutions were prepared in methanol/water (1:1, v/v) for LPA; in ethanol for AITC, capsaicin and DGPP; in methanol for capsazepine; and in dimethylsulfoxide (Wako) for all other compounds.
Behavioural test
A cheek injection model (Shimada & LaMotte, 2008) was used in this study without any anaesthesia. After a 30 min habituation, 10 μl of saline-based vehicle or LPA (8.94, 100 or 300 nmol prepared from the commercially supplied powder) was intradermally injected into the right cheek of the mice with a 30-gauge needle (Becton Dickinson and Company, Franklin Lakes, NJ, USA) connected to a glass syringe (Hamilton Company, Reno, NV, USA) by PE-10 polyethylene tubing (Becton Dickinson and Company). Behaviours were then recorded for 30 min with a digital camera (EX-ZR100 and EX-ZR400, CASIO, Tokyo, Japan). Inhibitors were co-injected at a concentration of 200 nmol per 10 μl. Scratching and wiping behaviours directed toward the injection site were counted. A set of scratching bouts was defined as a serial movement wherein the mouse lifts its hindpaw for scratching and subsequently returns the hindpaw to the floor. Wiping behaviour was defined as only unilateral behaviour with the forelimb.
Cultures of isolated TG and DRG neurons
The TG and DRG were rapidly dissected from adult C57BL/6NCr mice upon anaesthesia with intramuscular injection of ketamine (100 mg kg −1 ) and intraperitoneal injection of xylazine (10 mg kg −1 ), and then dissociated by incubation for 20-30 min at 37°C in Earle's balanced salt solution (EBSS; Sigma) containing 10% fetal bovine serum (FBS; Biowest, Nuaille, France), 2 mM L-glutamine (GlutaMAX; Thermo Fisher Scientific), vitamin mixture (C6895; Sigma), 50 units ml −1 penicillin/50 μg ml −1 streptomycin (Thermo Fisher Scientific) and 2.5 mg ml −1 collagenase (C7657; Sigma). After changing the solutions by centrifugation (room temperature, 1000 r.p.m., 4 min), the TG and DRG were gently triturated with a fire-polished Pasteur pipette and filtered through 70 μm nylon mesh (Becton Dickinson and Company). The solution was changed to Dulbecco's modified Eagle's medium (DMEM; Wako) containing 10% FBS, 50 units ml −1 penicillin/50 μg ml −1 streptomycin and 2 mM L-glutamine. TG and DRG neurons were re-suspended in DMEM, inoculated in a drop on 12 mm coverslips (Matsunami Glass Ind., Osaka, Japan) pre-coated with poly-D-lysine (100 μg ml −1 , C6407; Sigma), and incubated for 30 min at 37°C in 5% CO 2 followed by medium addition. Cultured DRG neurons were used for Ca 2+ imaging experiments 14-24 h after dissection.
Ca
2+ imaging
For Ca 2+ imaging experiments, DRG and TG neurons were incubated for 30 min in medium containing 5 μM of the fluorescent indicator Fura-2. Fura-2 fluorescence was measured under conditions where a coverslip was set in a recording chamber that was then perfused with a standard bath solution containing 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , 2 mM CaCl 2 , 10 mM Hepes and 10 mM D-glucose at pH 7.4 adjusted with NaOH. A Ca 2+ -free bath solution was prepared by omitting 2 mM CaCl 2 from the standard bath solution and adding 5 mM EGTA. Ionomycin (5 μM) was applied to confirm cell viability and for response normalization with the equation described below. Antagonists/inhibitors were applied 90 s before LPA application and for 90 s with 5 μM LPA in experiments using those compounds. Fura-2 fluorescence was excited at 340 and 380 nm and emission was monitored at 510 nm with a digital CCD camera (ORCA-HR C4742-95-12HR; Hamamatsu Photonics, Hamamatsu, Japan). Data were obtained every 5 s and analysed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The 340/380 ratio value (described as F) was calculated using regions of interest that included the whole cell body. The change in the 340/380 ratio value ( F Norm ) was normalized using the following formula:
where F Initial is the averaged F for the first 25 s of each cell in the experiments, and F Ionomycin is the maximum F value of ionomycin application for 100 s. In this study, each response to an application with F Norm ࣙ 0.1 was regarded as positive. Cells not responding to KCl (100 mM) application were regarded as non-neuronal cells. Dose-dependency of the Ca 2+ imaging data (acquired with IP Lab software) was fitted with the equation 
RNA extraction and reverse transcription PCR
Total RNA was extracted from freshly isolated mouse DRG neurons that were isolated as described above. DRGs were collected into a 1.5 ml tube (Nippi Incorporated, Tokyo, Japan) and homogenized in Sepasol-RNA I Super G (Nacalai Tesque, Kyoto, Japan). RNA extraction was performed by incubation at room temperature forJ Physiol 595.8 Table 1 . Primer sets for mouse LPA receptors and phospholipases
Genes
Sense primer (5 →3 ) Antisense primer (5 →3 )
500 μl 2-propanol (Nacalai Tesque) was added to the supernatant, which was incubated at room temperature for 10 min and centrifuged at 12 000 g and 4°C for 10 min. The resulting precipitate was resuspended in 1 ml 75% (v/v) ethanol (Wako), centrifuged at 12 000 g and 4°C for 5 min, and the supernatant was removed.
Extracted RNA was treated with DNase I following the manufacturer's protocol. The solution was mixed with an equivalent amount of phenol/chloroform/isoamyl alcohol (25:24:1, PCI) (Nacalai Tesque). RNA was purified through centrifugation at 12 000 g and room temperature for 10 min, mixing the supernatant with an equivalent amount of PCI, and centrifuging at 12 000 g and room temperature for 10 min. Then, 3 M sodium acetate (pH 5.2, Nacalai Tesque) and 100% ethanol (Wako), at one-tenth and 2.5 times, respectively, of the total supernatant volume was added to the supernatant followed by mixing and incubation at −20°C for 20 min followed by centrifugation at 12 000 g and 4°C for 10 min. Ethanol (70%, 1 ml; Wako) was added before the suspension was centrifuged at 12 000 g and 4°C for 5 min, and the supernatant was then removed.
Reverse transcription was performed using 1 μg extracted RNA and SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) following the manufacturer's protocol. PCR was performed on a reaction mixture including cDNA, each primer set (Table 1 ) and recombinant Taq DNA Polymerase (R001A; Takara Bio Inc., Shiga, Japan) following the manufacturer's protocol. After incubation at 95°C for 5 min, 35-40 cycles of PCR were performed with 95°C for 45 s, 60°C for 30 s and 72°C for 10 s, followed by incubation at 72°C for 10 min. The PCR products were electrophoresed on a 1.5% agarose (Thermo Fisher Scientific) gel with 0.5 μg ml −1 ethidium bromide (Thermo Fisher Scientific) at 100 V for 30-40 min and visualized with a transilluminator (ATTO, Tokyo, Japan).
RNA interference (RNAi) for mLpa5
RNAi was performed by transfection of mixed small interference RNAs (siRNAs) specific for mLpa5 (Thermo Fisher Scientific) with a total amount of 1000 pmol siRNA for one DRG neuron culture coverslip. The sequences used were CCCUCAGAAAGCACCCAAAtt, CCACUGGUUUACUACUUCAtt and CCCUCAGAAAG CACCCAAAtt. For negative control siRNA, Silencer Negative Control No. 1 siRNA (Thermo Fisher Scientific) was transfected. Transfection was performed with Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific) following the manufacturer's protocol.
Transient transfection of HEK293T cells
HEK293T cells were maintained at 37°C in 5% CO 2 in the supplemented DMEM described above. Transient transfection of HEK293T cells was achieved with Lipofectamine Transfection Reagent (Thermo Fisher Scientific), PLUS Reagent (Thermo Fisher Scientific) and Opti-MEM I Reduced Serum Medium (Thermo Fisher Scientific) following the manufacturer's protocol. Plasmid DNAs for TRPA1 (pcDNA5-FRT) and TRPV1 (pcDNA3.1) were transfected with pGreen Lantern 1 into HEK293T cells and transfected cells were used for patch clamp experiments 14-48 h after transfection. For mlpa5 RNAi experiments, the mLpa5/pEGFP-N2 vector was transfected.
Electrophysiology
HEK293T cells expressing mTRPA1 or mutant mTRPA1 were used for whole-cell and single-channel recordings with standard patch pipettes (3-5 M resistance) made with borosilicate glass capillaries (King Precision Glass, Claremont, CA, USA). The extracellular solution for whole-cell recording was the standard bath solution mentioned above. The extracellular solution for single-channel recording and the intracellular solutions for both configurations contained 140 mM KCl, 5 mM EGTA and 10 mM HEPES at pH 7.4, adjusted with KOH. The whole-cell voltage-clamp recordings were performed with the membrane potential clamped at −60 mV. Inside-out membrane patches were used for single-channel recordings where the membrane potential 
TTCAAGAAGGAGcaGCTGGAACAGATG CATCTGTTCCAGCtgCTCCTTCTTGAA was clamped at +30 mV. Before membrane excision, cells were perfused with the standard bath solution that was then exchanged for the KCl-based solution. Data were sampled at 10 kHz and filtered at 5 kHz for whole-cell recording and at 2 kHz for single-channel recording (Axopatch 200B Amplifier; Molecular Devices, Sunnyvale, CA, USA). Data were analysed using pCLAMP 10.2 Software (Molecular Devices).
Construction of mutant mouse TRPA1
mTRPA1 (NM 177781) cDNA in the pcDNA5/FRT expression vector was used. Vectors containing mTRPA1 mutants were constructed by PCR with synthesized oligonucleotide primer sets containing specific nucleotide sequences that produced amino acid substitutions ( Table 2 ). The entire sequence of each mTRPA1 including the desired substitutions was confirmed by DNA sequencing.
Statistics
Data are expressed as means ± SEM. No data points were excluded. All statistical analyses were conducted on at least three different experiments. Statistical analyses were performed with the two-tailed Welch's t test to compare two groups and with one-way ANOVA tests followed by two-tailed Dunnett's tests for multiple comparisons, unless mentioned specifically in the figures. P < 0.05 was considered to be significant.
Results
LPA-induced behaviours in a mouse cheek injection model
In mice, LPA has been reported to induce scratching behaviours (Hashimoto et al. 2004; Kremer et al. 2010; Alemi et al. 2013 ) and pain-related responses (Nieto-Posadas et al. 2012) , leading to ambiguity about its physiological effects. Itch-and pain-related behaviours are clearly segregated as scratching and wiping behaviours that occur in response to pruritogens and algogens, respectively (Akiyama et al. 2010a ). We used a cheek injection model (Shimada & LaMotte, 2008) to clarify a physiological role for LPA in mice. LPA (100 nmol per site) was intradermally injected into the right cheeks of wild type (WT) mice, and subsequent scratching and wiping behaviours were counted. The LPA-induced scratching behaviours peaked at 20 min following injection (Fig. 1A ), but no significant wiping behaviours were observed (Fig. 1B) . Compared with vehicle treatment, the scratching behaviour continued during the first 30 min after injection of LPA (Fig. 1C ), but no wiping behaviours were seen ( Fig. 1D ). Thus, in mice LPA acts as a pruritogen, but not an algogen. Because LPA-induced acute pain-related behaviours were previously reported (Nieto-Posadas et al. 2012), we performed the cheek injection assay at the same LPA dose (8.94 nmol) and no wiping behaviours were observed (Fig. 1E) . A three times higher dose of LPA (300 nmol per site) also failed to induce wiping behaviours,
but did induce scratching behaviours (Fig. 1F) , again confirming that LPA works as a pruritogen without effects as an algogen.
LPA-induced Ca 2+ influx through TRPA1 and TRPV1 channels in mouse DRG neurons
To examine whether LPA directly affects mouse TG and DRG neurons, Ca 2+ imaging experiments were performed using primary cultured TG and DRG neurons. Application of LPA (5 μM) transiently caused similar increases in intracellular Ca 2+ concentrations ([Ca 2+ ] i ) in both DRG and TG neurons ( Fig. 2A and E) . Therefore, we decided to use DRG neurons in the following experiments because it was easier to obtain a large number of cells from the DRG, which could make the data more convincing. LPA-responding neurons were found in 40.0 ± 3.5% (n = 394/1030) of the examined DRG neurons, which were classified as LPA-responding (LPA + ) ( Fig. 2A, D and F ).
This LPA effect was dose-dependent, and the EC 50 value for the intensity of LPA + neurons was 1.1 ± 0.3 μM (Fig. 2B) (Caterina et al. 2000; Story et al. 2003; Bautista et al. 2006; Shim et al. 2007; Wu et al. 2010; Wilson et al. 2011 Wilson et al. , 2013 Morita et al. 2015) . To examine the functional expression of these channels in LPA + DRG neurons, AITC (100 μM) and capsaicin (Cap, 1 μM), which are selective agonists of TRPA1 and TRPV1, respectively, were applied after LPA treatment (Fig. 2D) .
Based on the responsiveness to LPA, AITC and Cap, DRG neurons were classified into eight subpopulations To further examine whether activation of TRPA1 and/or TRPV1 was involved in the Ca 2+ influx induced by LPA, the TRPA1 antagonist A-967079 (A96, 1 μM) and TRPV1 antagonist capsazepine (CPZ, 10 μM) were applied to the neurons prior to LPA addition. Individually, both antagonists decreased the number of LPA + neurons, and co-application of the two antagonists almost completely abolished LPA + neurons (Fig. 3A) . To further clarify the contribution of TRPA1 and/or TRPV1 to LPA responsiveness, DRG neurons from mice lacking TRPA1 (TRPA1KO), TRPV1 (TRPV1KO) or both channels (TRPA1TRPV1DKO) were assessed. The number of LPA + neurons significantly decreased in TRPA1KO, TRPV1KO and TRPA1TRPV1DKO DRG neurons (26.0 ± 6.0%, J Physiol 595.8 n = 144/579; 20.3 ± 2.8%, n = 93/443; and 13.5 ± 3.2%, n = 65/455, respectively) (Fig. 3B) . Taken together, these results suggested that the LPA-induced [Ca 2+ ] i increase in DRG neurons is evoked mainly through activation of TRPA1 and/or TRPV1.
Involvement of TRPA1 and TRPV1 in LPA-induced scratching
To examine the contribution of TRPA1 and/or TRPV1 to LPA-induced scratching behaviours, LPA was injected into the cheeks of WT, TRPA1KO, TRPV1KO and TRPA1TRPV1DKO mice. Scratching behaviours were reduced in each mouse type (Fig. 3C) to levels that were similar to that seen for the vehicle-treated group (Fig. 1C) . No changes in wiping behaviours were observed in these strains (Fig. 3D) , indicating that both TRPA1 and TRPV1 are involved in LPA-induced scratching but not wiping (i.e. pain) behaviours. Thus, results from in vivo and in vitro experiments to explore the mechanism of LPA action suggested that TRPA1 and TRPV1 play crucial roles in LPA-induced itch sensation.
LPA receptors are involved in an LPA-induced [Ca 2+ ] i increase in DRG neurons
Given that the TRPA1 + and TRPV1 + populations were not well encompassed by the LPA + population (Fig. 2F) , we hypothesized that indirect mechanisms initiated by LPA receptor activation, as well as direct activation of TRPA1 and TRPV1 by LPA, are involved in LPA activity. We first investigated if LPA receptors are involved in the LPA-induced [Ca 2+ ] i increase seen in DRG neurons. The six known LPA receptors are G protein-coupled receptors that are currently referred to as LPA 1 -LPA 6 (Kihara et al. 2014) . While diverse expression patterns for these receptors are known in various organs (Choi et al. 2010) , LPA 1 , LPA 3 and LPA 5 , which all cause [Ca 2+ ] i increases in response to LPA (Fischer et al. 2001; Lee et al. 2006) , are reportedly expressed in DRG neurons (Inoue et al. 2004; Lee et al. 2006; Nieto-Posadas et al. 2012) . We confirmed this expression in the DRG neurons by RT-PCR (Fig. 4A) . To investigate the involvement of these three LPA receptors, we first tested the antagonist H2L 5765834 (H2L) . E, percentages of LPA-responsive neurons in negative-control siRNA-or mLpa5 siRNA-transfected neurons; n = 4 and 6 coverslips treated with negative-control siRNA or mLpa5 siRNAs, respectively. F, [Ca 2+ ] i changes in siRNA-transfected DRG neurons upon application of 5 μM LPA; n = 23 and 32 for negative-control siRNA-and mLpa5 siRNA-transfected neurons, respectively. * P < 0.05 by Welch's t test.
J Physiol 595.8 receptors. H2L (10 μM) decreased the number of LPA + neurons (8.8 ± 3.5%, n = 45/347) (Fig. 4B ), indicating that one or more of these three LPA receptors mediated the LPA-induced [Ca 2+ ] i increase in DRG neurons. To determine which LPA receptor subtype had the most significant role in LPA-induced DRG responses, an antagonist specific to each LPA receptor was next used. The highly selective LPA 1 antagonist AM095 (10 μM) partially reduced the number of LPA + neurons (27.4 ± 1.7%, n = 119/457), although this change was not statistically significant (Fig. 4B) . Meanwhile, the LPA 3 antagonist DGPP (10 μM) had little effect on the LPA + population (35.3 ± 6.5%, n = 158/514) (Fig. 4B) . In contrast, TC LPA5 4 (TC, 10 μM), a selective antagonist of LPA 5 , markedly decreased the number of LPA + neurons (4.9 ± 1.8%, n = 16/340) (Fig. 4B) (Fig. 4F) were significantly decreased. Together, these results suggested that LPA 5 is the most likely LPA receptor to be involved in the LPA-induced Ca 2+ response in mouse DRG neurons.
Downstream pathways of LPA receptors in DRG neurons
Although the LPA 5 receptor was found to be involved in LPA-induced [Ca 2+ ] i increases in mouse DRG neurons, the finding that LPA-induced [Ca 2+ ] i increases nearly disappeared in the absence of extracellular Ca 2+ and upon co-application of the TRP antagonists A967079 and Cap ( Fig. 2C and 3A) suggests the possible existence of mechanisms that are induced by LPA 5 receptor activation to promote Ca 2+ influx through TRPA1 and/or TRPV1 channels. Given the uncertainty about whether multiple G protein-coupled LPA receptors expressed in the same cells interact with one another, and how complex G-protein signalling is involved in itch-related intracellular pathways (Choi et al. 2010; Kihara et al. 2014) , exploration of critical molecules or pathways that are downstream targets of the LPA receptor and lead to activation of TRPA1 and TRPV1 channels is important. Intracellular lipid production and phospholipid depletion by phospholipase activity could possibly activate TRPA1 and TRPV1 (Dai et al. 2007; Rohacs et al. 2008; Kukkonen, 2011) following LPA 5 activation. Therefore, we focused on the phospholipases and pathways that are thought to produce putative TRPA1 and TRPV1 ligands. We hypothesized that Ca 2+ -independent phospholipase A 2 (iPLA 2 ) (Dennis et al. 2011) , phosphatidylcholine-specific phospholipase C (PC-PLC) (Adibhatla et al. 2012 ) and phospholipase D (PLD) (Selvy et al. 2011 ) activities may be involved in the ligand production (Fig. 5A) . RT-PCR analysis showed that both iPLA2 (Pla2g6) and PLD (Pld1 and Pld2) are expressed in DRG neurons (Fig. 5B) . We also confirmed the expression of the phosphatidylinositol-specific phospholipase C (PI-PLC) gene (Plcb3), because this enzyme has also been reported to be involved in itch sensation (Han et al. 2006; Imamachi et al. 2009; Wilson et al. 2013) (Fig. 5A and B) .
An inhibitor of PC-PLC (D609, 10 μM) that produces diacylglycerol (DAG) and phosphorylcholine (Adibhatla et al. 2012) (Fig. 5A) did not affect the LPA + neuron population (30.6 ± 403%, n = 126/403) (Fig. 5C ), suggesting that PC-PLC activity and products are not required for the response of DRG neurons to LPA. PI-PLC cleaves membrane PI 4,5-bisphosphate (PIP 2 ) to produce DAG (Fig. 5A ) and inositol 1,4,5-trisphosphate (IP 3 ) to cause an increase in [Ca 2+ ] i from IP 3 -dependent Ca 2+ stores (Kadamur & Ross, 2013) . We examined this enzyme because previous reports indicated that PI-PLC and PI-PLC signalling-related products were related to itch sensation (Han et al. 2006; Imamachi et al. 2009; Wilson et al. 2013) as well as TRPA1 and TRPV1 activation (Bandell et al. 2004; Woo et al. 2008) . The selective PI-PLC inhibitor U-73122 exhibited non-specific effects in DRG neurons (data not shown), as previously reported in Chinese hamster ovary (CHO) cells expressing TRPA1 and in DRG neurons (Kim et al. 2011; Bandell et al. 2004; Karashima et al. 2008) . Therefore, we used another PI-PLC inhibitor, edelfosine (Edel, 10 μM), which decreased the number of LPA + neurons (13.4 ± 3.3%, n = 43/318) (Fig. 5C ), indicating that PI-PLC activity is indeed involved to some extent in LPA-induced signalling in DRG neurons.
PLA 2 activity produces lysophospholipids (LPLs) (Fig. 5A ) and fatty acids (Dennis et al. 2011) , both of which can activate several ion channels, including TRPs (Kukkonen, 2011) . A specific inhibitor of iPLA 2 , BEL (1 μM), decreased the number of LPA + neurons (17.5 ± 4.7%, n = 118/694) (Fig. 5C ), suggesting that iPLA 2 activity is involved in the LPA pathway. Meanwhile, PLD hydrolyses phospholipids and LPLs into PA and LPA (Selvy et al. 2011) , respectively, and PA can be further hydrolysed to fatty acids and LPA by subsequent PLA 2 activity (Thomson & Clark, 1995; Choi et al. 2010; Tigyi, 2010; Kukkonen, 2011) (Fig. 5A) . The potent PLD-specific inhibitor FIPI (10 μM) almost abolished LPA + neurons (3.5 ± 0.7%, n = 8/237) ( Fig. 5C and D) , suggesting that products generated by PLD activity are strongly involved in the LPA-induced [Ca 2+ ] i response in DRG neurons. These results demonstrated the involvement of PI-PLC, iPLA 2 and especially PLD in the LPA-induced response in DRG neurons and suggested that, among the phospholipases, PLD may play the most crucial role in LPA signalling.
Direct activation of TRPA1 by LPA
DAG, LPC, LPI, PA and LPA could be produced by the enzymatic activity of PI-PLC, iPLA 2 and PLD (Fig. 5A) (Fig. 3A and B) , raise the possibility that these molecules may directly activate TRPA1 and/or TRPV1 intracellularly. An earlier report showed that a DAG analogue activates TRPA1 (Bandell et al. 2004) , and the effects of DAG, phospholipids 
PLD is required for LPA-induced signalling in DRG neurons
A, hypothetical intracellular cascades of various lipid products upon LPA receptor activation. Processing of membrane lipids such as PC and PI can be catalysed by multiple phospholipases such as PC-PLC, PI-PLC, iPLA 2 and PLD (arrows) to produce various lipids, including DAG, LPC, LPI, PA and LPA. Phospholipase inhibitors are indicated in blue. BEL, bromoenol lactone; DAG, diacylglycerol; Edel, edelfosine; iPLA 2 , calcium-independent phospholipase A 2 ; LPC, lysophosphatidylcholine; LPI, lysophosphatidylinositol; PA, phosphatidic acid; PC, phosphatidylcholine; PC-PLC, PC-specific phospholipase C; PI, phosphatidylinositol; PI-PLC, PI-specific phospholipase C; PLD, phospholipase D. Dotted lines indicate uncertain enzymatic pathways. Grey lines, red circles, orange diamonds and pink diamonds indicate hydrocarbon chains, phosphate groups, phosphorylcholine and inositol phosphate, respectively. B, expression of mouse iPLA 2 , PLCβ3, PLD1 and PLD2 genes (mPla2g6, mPlcb3, mPld1 and mPld2, respectively) in DRG neurons examined in RT-PCR experiments. Equivalent results were obtained from at least three independent tests of samples isolated from other mice. C, percentages of LPA-responding DRG neurons from WT mice during application of LPA (5 μM) alone and LPA with phospholipase inhibitors, including D609 (10 μM), Edel (10 μM), BEL (1 μM) and FIPI (10 μM); n = 5-13. Cells ࣙ 200. * * P < 0. and LPLs on TRPV1 function have also been examined (Brauchi et al. 2007; Nieto-Posadas et al. 2012) . Therefore, to examine whether DAG analogues directly activate TRPA1 and TRPV1 channels from the intracellular side, we applied LPC, LPI, PA or LPA onto the intracellular side of the plasma membrane of HEK293T cells expressing either TRPA1 or TRPV1. LPA, but not LPC, LPI or PA, strongly induced unitary single-channel currents of TRPA1 or TRPV1 (Fig. 6B-E) , suggesting that LPA is the most likely product of the phospholipases that can activate both channels. No currents were induced by LPA in patch membranes that lacked TRPA1 and TRPV1 expression (Fig. 6A) . LPA-induced single-channel currents of TRPA1 and TRPV1 were significantly inhibited by the antagonists A967079 (1 μM) and capsazepine (10 μM), respectively ( Fig. 6D-G) , which supports the idea that LPA activates TRPA1 and TRPV1.
Given that the ability of LPA to activate TRPA1 from the extracellular side was unclear, and that LPA-dependent TRPV1 activation was previously demonstrated (Nieto-Posadas et al. 2012), we also examined whether LPA activates TRPA1 and TRPV1 extracellularly in whole-cell patch-clamp recordings.
Interestingly, LPA did not induce inward currents in the cells that responded to AITC or capsaicin, (Fig. 6H and  I) , suggesting that LPA activates both TRPA1 and TRPV1 intracellularly, but not extracellularly.
Identification of the amino acids involved in TRPA1 activation by LPA
Interactions of phospholipids such as PIP 2 with ion channels and the detailed interaction sites have been well studied (Suh & Hille, 2008) , and thus specific amino acids that govern the interaction between TRPV1 and LPA could be identified based on the fact that the entire LPA structure is included in PIP 2 (Nieto-Posadas et al. 2012) . Therefore, we tried to identify the amino acid residues involved in LPA-induced activation of TRPA1 by focusing on the 'putative pleckstrin homology (PH)-like domain' defined
arginine; X: any amino acid), which is predicted to be involved in the effect of PIP 2 on TRPA1 . Considering the negative charges of LPA and PIP 2 , the positively charged PH-like domains would be candidates for the LPA and TRPA1 interaction. Among the four PH-like domains (PH-like 1-4) in TRPA1 (Karashima et al. 2008) , we focused on the PH-like domains 3 and 4 because these sites are located near the transmembrane domains (Paulsen et al. 2015) , and in other ion channels many phospholipid interaction sites have been shown to exist near the transmembrane domains (Suh & Hille, 2008) . We also focused on the subcellular K/R-rich regions that are located close to the transmembrane domains and other nearby serial K/R residues (Fig. 7A) . In total, 26 K and R amino acids were chosen as candidate residues for involvement in the interaction of LPA with TRPA1. Single-channel analyses in HEK293T cells expressing WT or mutated TRPA1 channels identified two mutants (KK672-673QQ and KR977-978QQ) that showed markedly reduced NP o (number of channels times open probability) values (0.09 ± 0.05 and 0.13 ± 0.04, respectively) relative to WT TRPA1 (0.35 ± 0.07) following LPA application (Fig. 7B) , while considerable responses to the TRPA1 agonists, carvacrol (500 μM) and AITC (100 μM), were maintained (Fig. 7C ). These data indicated that these four basic residues are likely to be involved in TRPA1 activation by LPA.
PLD activity is required for LPA-induced itch in vivo
PLD activity was shown to be crucial for LPA-induced [Ca 2+ ] i responses in DRG neurons ( Fig. 5C and D) . Therefore, to ascertain if PLD activity is responsible for LPA-induced itch sensation in vivo, we performed cheek injection experiments. LPA-induced scratching behaviours were decreased by co-application with FIPI (200 nmol/10 μl per site) (Fig. 8A ) without significant changes in wiping behaviours (Fig. 8B) , suggesting that the decrease in scratching induced by FIPI is not compensated K K 6 7 2 -6 7 3 Q Q K R 7 9 9 -8 0 0 Q Q K R 9 7 7 -9 7 8 Q Q K K 9 9 1 -9 9 2 Q Q R K 9 9 9 -1 0 0 0 Q Q K 9 7 2 Q R 5 9 3 Q K 5 9 4 Q R 6 0 2 Q K 6 0 4 Q R for by an increase in wiping behaviours. In contrast, co-application of LPA with the PLC inhibitor D609 (200 nmol/10 μl per site) did not significantly affect LPA-induced scratching and wiping behaviours ( Fig. 8C  and D) , which is consistent with the result that D609 did not evoke LPA-induced [Ca 2+ ] i responses in DRG neurons (Fig. 5C ). These results suggested that PLD activity is required for LPA-induced itch sensation in vivo as well as the LPA-induced [Ca 2+ ] i response observed in DRG neurons in vitro.
Discussion
In this study we demonstrated that LPA is a pruritogen, but not an algogen, and that DRG neurons respond to LPA through activation of TRPA1 and TRPV1. Notably, PLD activity is required for LPA-induced signalling downstream of LPA 5 activation. We also demonstrated that LPA, a PLD activity-mediated product, directly activates TRPA1 from the intracellular side. Combined with the report regarding TRPV1 (Nieto-Posadas et al. 2012) , these findings support our hypothesis that LPA 5 activation by extracellular LPA induces de novo production of intracellular LPA via PLD and iPLA 2 activity that subsequently leads to TRPA1 and TRPV1 activation (Fig. 9) . Importantly, PLD activity as well as that of TRPA1 and TRPV1 is required for LPA-induced pruritus, suggesting that the LPA signalling observed in vitro could also occur in vivo.
The ambiguity concerning whether LPA functions as a pruritogen or algogen that arose from results of previous behavioural studies (Hashimoto et al. 2004; Kremer et al. 2010; Nieto-Posadas et al. 2012; Alemi et al. 2013) can partly be explained by the lack of definition or distinction between possible pain-related licking behaviours and biting behaviours. Since licking and biting of the hindpaws can be induced by algogens and pruritogens, respectively, it is difficult to readily discriminate between the two. Well-defined biting behaviours toward the hindpaws that were induced by pruritogenic conditions or pruritogens were observed in a dry-skin model in mice (Akiyama et al. 2010b) and by serotonin injection into the hindpaw (Kuraishi et al. 2008) . Because of the difficulty in distinguishing between the two behaviours, particular attention should be paid to compounds that have uncharacterized effects (Akiyama & Carstens 2013; Han & Dong, 2014) . Taking these facts into consideration, several compounds that appeared to have both algogen and pruritogen properties were confirmed to be pruritogens by cheek injection experiments (Shimada & LaMotte, 2008; Akiyama et al. 2010a; Wilson et al. 2011 Wilson et al. , 2013 Morita et al. 2015) . In this study the cheek injection results support a role for LPA as a pruritogen.
In healthy humans, serum LPA concentrations are typically in the submicromolar range (Hosogaya et al. 2008) , which is lower than the concentration (5 μM) we used in this study. As such, LPA may not activate primary sensory neurons under healthy conditions, but high-level LPA production could induce itch sensations in cholestasis patients, although the correlation between LPA concentrations and activity of LPA-producing enzymes under pruritic condition awaits examination. However, the measurement of plasma LPA levels is challenging due to the rapid degradation of LPA by lipid phosphate phosphatases such that the half-life of plasma LPA is about 3 min (Albers et al. 2010) . Nonetheless, a good correlation between serum LPA-producing activity and itch intensity in cholestatic patients with pruritus (Kremer et al. 2010) suggests that a high LPA concentration is sufficient to activate peripheral sensory neurons, resulting in itch sensations.
In this study we showed that TRPA1 and TRPV1 are required for LPA-induced signalling in DRG neurons and LPA-induced pruritus in vivo (Figs 2 and 3) . Interestingly, the in vivo results showed that ablating either of the two channels is sufficient to diminish LPA-induced pruritus to the levels seen for vehicle treatment ( Figs 1C  and 3B ). These observations suggest a possible mechanism for LPA-induced itch signalling and scratching in vitro and in vivo: a decrease in the total number of LPA + neurons in TRPA1KO or TRPV1KO mice could fully decrease LPA-induced pruritus. These outcomes could partly be explained by potential functional interactions between the two channels during pain signalling (Weng et al. 2015) . Thus, TRPA1 and TRPV1 could contribute to LPA action separately or in concert. Indeed, pruritus that was dependent on both TRPA1 and TRPV1 was previously reported to be caused by LTB 4 and IL-31 (Fernandes et al. 2013; Cevikbas et al. 2014) . In the latter case, the TRPA1 + /TRPV1 + population was suggested to play a crucial role in itch signalling, which is similar to our findings.
We demonstrated the possible involvement of iPLA 2 , PI-PLC and, most critically, PLD in LPA signalling, all of which can be activated downstream of LPA receptor activation (Choi et al. 2010; Tigyi, 2010; Kukkonen, 2011) , although no highly specific enzyme inhibitors are available. However, the finding that LPA had no effect in whole-cell recordings ( Fig. 6H and I ) together with the unique activity of LPA among the above signalling pathways suggests that LPA produced de novo by both iPLA 2 and PLD leads to activation of TRPA1 and TRPV1 channels. Our results also suggest that PI-PLC is partially involved in LPA action, which is consistent with reports showing PI-PLC-dependent itch signalling induced by various pruritogens (Han et al. 2006; Imamachi et al. 2009; Wilson et al. 2011 Wilson et al. , 2013 . Collectively, LPA endogenously produced by PLD and iPLA 2 activity causes TRPA1 and TRPV1 activation (Fig. 9) .
We also used site-directed mutagenesis to identify for the first time the TRPA1 residues that are necessary for the interaction between LPA and TRPA1. Residues KK672-673 and KR977-978, which are located close to the transmembrane domains in the TRPA1 N-and C-terminus, respectively, were found to be important for the LPA-TRPA1 interaction. The location of these K and R residues is consistent with earlier findings that showed interactions between channels and phospholipids such as PIP 2 (Suh & Hille, 2008) . The TRPA1 structure was previously clarified by cryo-electron microscopy single-particle analysis (Paulsen et al. 2015) and phospholipid interaction sites were identified in TRPV1 (Brauchi et al. 2007; Nieto-Posadas et al. 2012) , but not all basic amino acid residues in TRPA1 were examined in this study. The reports showing that PIP 2 interaction sites are located on the distal N-terminal region of TRPV4 (Garcia-Elias et al. 2013; Takahashi et al. 2014) , one of which is a predicted PH-like domain , suggest that other phospholipid interaction sites could exist in TRPA1.
In addition to TRPA1 and TRPV1, we used phospholipase inhibitors to demonstrate the involvement of PLD in LPA-induced pruritus. LPA was identified as the most likely candidate pruritogen, which is consistent with the fact that serum LPA-producing activity correlates with itch intensity of cholestatic patients with pruritus (Kremer et al. 2010) . On the other hand, bile acids, which are increased in cholestasis but not correlated to itch intensity (Kremer et al. 2010) , were recently shown to induce pruritus in mice through the TGR5 receptor (Alemi et al. 2013 ) and TRPA1 (Lieu et al. 2014) . These apparently different phenomena might be due to differences between humans and mice or the acute and chronic phases of cholestatic disease. Furthermore, bile duct ligation in cholestatic rats induced forepaw and hindlimb scratching behaviours that are thought to be related to the PAR2 receptor and TRPV1, as evidenced by increases in the expression levels of these proteins (Belghiti et al. 2013) . Therefore, the establishment of a cholestatic mouse model would be necessary to elucidate whether our hypothetical pathway that involves LPA 5 , PLD, TRPA1 and TRPV1 (Fig. 9) is physiologically relevant for inducing pruritus. 
